Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The user experienced reduced hair loss after switching from finasteride and dutasteride to consuming fruit seeds like pumpkin and flaxseed, but others suggest the improvement is likely due to the delayed effects of the medications. There is skepticism about the seeds' effectiveness in blocking DHT compared to the medications.

Hair loss is often linked to inflammation and DHT, with treatments like finasteride, dutasteride, and minoxidil being effective for many. Natural remedies like turmeric and oils are discussed, but medications are generally seen as more reliable for managing genetic hair loss.

The user has been on a comprehensive hair loss treatment regimen for four years, including Dutasteride, topical and oral Minoxidil, and various other treatments, but has seen little progress and is considering a hair transplant. Despite trying multiple therapies, including PRP and exosome injections, the user is still experiencing hair thinning and is hesitant about trying peptides due to potential cancer risks.

Finasteride and minoxidil help maintain hair and slightly improve hairlines but are less effective at regrowing hair in bald areas, often needing a hair transplant for full restoration. Many users report no side effects and wish they had started treatment earlier.

The user stopped oral treatments due to side effects and switched to a regimen of topical minoxidil, tretinoin, azelaic acid, and dermaneedling, with recent addition of topical finasteride. They are questioning the long-term effectiveness of non-hormonal methods and considering hair transplantation.

Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation humorously discusses hair loss treatments, focusing on finasteride, dutasteride, minoxidil, and microneedling. Users share experiences and opinions on the effectiveness and side effects of these treatments.

A user shared their hair transplant update, having received 4,300 grafts and choosing not to use medications like finasteride or minoxidil due to potential side effects and personal reasons. Many commenters expressed concern that without these medications, the user might experience further hair loss, suggesting that preventative treatments are important for maintaining transplant results.

The user had a hair transplant and uses oral minoxidil, a red laser therapy helmet, fish oil, collagen, and sardines for hair thinning but avoids finasteride due to side effect concerns. Many suggest these methods may not be effective long-term without a DHT blocker.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

In Austria, finasteride prescriptions are restricted due to suicide risk concerns, with new prescriptions only for current users. Alternatives like topical finasteride, dutasteride, and online purchases face legal challenges.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The user experienced severe sexual side effects from topical finasteride with minoxidil but found no side effects with low-dose dutasteride and finasteride serums from Ulo after a hair transplant. They also used a hair growth serum with saw palmetto without side effects.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

Ketoconazole 2% shampoo effectively regrew hair by treating scalp dermatitis and inflammation. The user also used jojoba and oat oil, Aveeno moisturizer, and hyaluronic acid for scalp care.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

The user shares a positive experience with Dutasteride for hair loss, noting increased hair density and minimal side effects after switching from Finasteride. They prefer oral Dutasteride and avoid Minoxidil due to its inconvenience and potential risks.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.

The user experienced significant hair regrowth and improved hair health after 5 months of using 0.5mg finasteride and 2.5mg minoxidil daily, with only minor side effects like reduced libido. The user is optimistic about achieving over 90% regrowth and may not need a hair transplant.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

The user experienced initial regrowth with finasteride and minoxidil but is now facing increased hair thinning, possibly due to a second shedding phase. They are considering increasing finasteride dosage or adding dutasteride, despite availability issues, and have started microneedling.